Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexandra Tiliakos

Rheumatology Lawrenceville, GA Medical Doctor

NPI 1407064447 CMS profile 62963

705 Walther Rd, Lawrenceville, GA 30046

Open in the dashboard

General payments

$6,875

446 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Tiliakos of Lawrenceville, GA is reported in the CMS Open Payments database as having received $6,875 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,050 111
2024 General $1,946 130
2023 General $1,200 79
2022 General $1,070 68
2021 General $264 23
2020 General $115 7
2019 General $231 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Tiliakos
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Alexandra Tiliakos were reported at $2,050. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Alexandra Tiliakos Rheumatology median Middle half National median
2019 $231 $744 $153–$2,687 $163
2020 $115 $462 $98–$2,027 $114
2021 $264 $531 $101–$2,153 $132
2022 $1,070 $627 $125–$2,303 $149
2023 $1,200 $741 $145–$2,524 $160
2024 $1,946 $830 $166–$2,660 $164
2025 $2,050 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,197 225 payments
  2. Amgen Inc. $975 57 payments
  3. Novartis Pharmaceuticals Corporation $593 40 payments
  4. Janssen Biotech, Inc. $579 33 payments
  5. Pfizer Inc. $304 32 payments
  6. UCB, Inc. $227 11 payments
  7. Mallinckrodt Hospital Products Inc. $225 10 payments
  8. E.R. Squibb & Sons, L.L.C. $179 8 payments
  9. Sobi, Inc $114 6 payments
  10. ANI Pharmaceuticals, Inc. $70 3 payments
  11. Other $412 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,755 441 payments
  2. Education $121 5 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,995 156 payments
  2. SKYRIZI Immunology $715 45 payments
  3. TREMFYA $492 26 payments
  4. COSENTYX $472 34 payments
  5. SKYRIZI Immunology $408 18 payments
  6. Otezla $406 20 payments
  7. Enbrel $340 23 payments
  8. XELJANZ $304 32 payments
  9. ACTHAR $225 10 payments
  10. ORENCIA $179 8 payments
  11. Other $2,115 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,058

Median for Rheumatology: 1,511

Drug cost

$1,467,361

Median for Rheumatology: $1,139,948

Branded share of claims

22.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 68 $509,327
Rinvoq Upadacitinib Brand 54 $350,931
Humira(Cf) Pen Adalimumab Brand 43 $292,561
Enbrel Etanercept Brand 14 $91,649
Xeljanz Xr Tofacitinib Citrate Brand 11 $70,935
Kineret Anakinra Brand 12 $66,887
Prolia Denosumab Brand 21 $36,054
Hydroxychloroquine Sulfate Generic 282 $10,550
Methotrexate Methotrexate Sodium Brand 343 $8,006
Gabapentin Generic 257 $3,828

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$133,166

Of which drugs: $44,552

Medicare patients

292

Average age 72

Services billed

6,680

247 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Osteoporosis 28%
Diabetes 25%
Ischemic heart disease 21%
Chronic kidney disease 21%
Depression 21%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,320 $27,077

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $625
$625 54 —
SKYRIZI
  • AbbVie, Inc. $387
$387 — —
TREMFYA
  • Janssen Biotech, Inc. $139
$139 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $134
$134 — —
Otezla
  • Amgen Inc. $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record